This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Genprex’s 8K filing here.
Genprex Company Profile
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
Featured Stories
- Five stocks we like better than Genprex
- What is diluted earnings per share (Diluted EPS)?
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Market Cap Calculator: How to Calculate Market Cap
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
